Freedom of Speech Upheld In Healthcare

  • by: |
  • 12/06/2012
"The First Amendment directs us to be especially skeptical of regulations that seek to keep people in the dark for what the government perceives to be their own good. " A US Appeals Court ruled that sharing scientific information about off-label uses of prescription drugs is protected by the First Amendment. Note to opponents of off-label information: you will still have plenty of chances to sue, attack, etc., since the Appeals court stated that then1st amendment doesn't protect misleading or deceptive speech. Which means that the trial bar and AGs will still seek damages under The False Claims Act. What should companies do? Generate clear guidelines on the level of evidence that should be used when sharing off-label information. Should a letter to NEJM discussing one doctor's observations about the novel use of medicine be widely shared? Probably not. But should a company be able to share information based on observational or registry research, comparative trials or new mechanisms of action? Yes. Similarly, companies should come up with a clear set of guidelines for talking about and responding about off label uses in social media. And I think it will be critical to develop a legal strategy reflecting this important ruling. For too long critics of the biopharma industry have been able to flood the digital commons with misleading, deceptive and sensationalist claims based on junk science. The appellate court ruling gives companies a bit more freedom to participate in conversations previously dominated by critics and fearmongers. They should use it or they might lose it.

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog